Nonresponsiveness to age-related macular degeneration (AMD) treatments has become a growing concern in ophthalmology. Disparity among publications that have assessed pharmacogenetic (PGx) connections between AMD disease genes and treatments has delayed the implementation of PGx testing in AMD. We assessed all AMD PGx publications to identify the degree of agreement for publications within similar ethnic cohorts and worldwide, and the causes for differences in study outcomes. There are no accepted genotype-phenotype correlations, either within similar ethnic cohorts or worldwide. The diversity of measured outcomes, treatment protocols and statistical methods used may be causing this discrepancy. A universally accepted treatment protocol and the creation of agreed response group classification may bridge the gap between AMD PGx publications.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.2217/pgs-2017-0183 | DOI Listing |
Lipids Health Dis
January 2025
Department of Ophthalmology, The First Affiliated Hospital of Nanchang University, Jiangxi Medical College, Nanchang University, Nanchang, Jiangxi, People's Republic of China.
Background: Age-related macular degeneration (AMD) decrease vision and presents considerable challenges for both public health and clinical management strategies. Obesity is usually implicated with increased AMD, and body mass index (BMI) does not reflect body fat distribution. An array of studies has indicated a robust relationship between body fat distribution and obesity.
View Article and Find Full Text PDFStrahlenther Onkol
January 2025
Klinik für Radioonkologie und Strahlentherapie, Universitätsmedizin Mainz, Langenbeckstr. 1, 55131, Mainz, Deutschland.
Sci Rep
January 2025
Department of Biochemistry and Molecular Biology, Faculty of Pharmaceutical Sciences, Tokyo University of Science, 2641 Yamazaki, Noda, Chiba, 278-8510, Japan.
Age-related macular degeneration (AMD) is a major cause of vision loss among adults. We investigated the protective effects of passion fruit seed extract (PFSE) and its rich polyphenol piceatannol in an AMD cell model in which human retinal pigment epithelial ARPE-19 cells were exposed to hydrogen peroxide (HO). Using a cell viability WST-8 assay, we revealed that PFSE and piceatannol increased the cellular viability of ARPE-19 cells by 130% and 133%, respectively.
View Article and Find Full Text PDFJ Clin Med
December 2024
Division of Ophthalmology, Department of Surgery, UMass Chan-Lahey School of Medicine, Burlington, MA 01805, USA.
Personalizing the management of neovascular age-related macular degeneration (nAMD) poses significant challenges for practicing retina specialists and their patients. This commentary addresses some of these complexities, particularly those that arise in the context of an expanding array of intravitreal agents targeting vascular endothelial growth factor (VEGF) and related retinal disease targets. Many of these newer agents approved by the Food and Drug Administration (FDA) for the treatment of nAMD have labeling that indicates that they can provide non-inferior visual outcomes when compared head-to-head with previously available treatments and can be used at significantly extended dosing intervals in some patients.
View Article and Find Full Text PDFEye (Lond)
January 2025
Department of Translational Biomedicine Neuroscience, University of Bari "Aldo Moro", Bari, Italy.
Background: To compare the characteristics of type 1 macular neovascularization (MNV) and the surrounding choriocapillaris (CC) perfusion in patients with neovascular age-related macular degeneration (nAMD) versus those with pachychoroid neovasculopathy (PNV) using swept-source optical coherence tomography angiography (SS-OCTA).
Methods: This retrospective study included 64 treatment-naïve eyes (37 nAMD, 27 PNV) with type 1 MNV. SS-OCTA images were analysed to measure MNV area and perimeter, and CC flow deficits (FD) in five concentric rings surrounding the lesion.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!